Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results

Francesca Gay, Valeria Magarotto, Claudia Crippa, Norbert Pescosta, Tommasina Guglielmelli, Federica Cavallo, Sara Pezzatti, Samantha Ferrari, Anna Marina Liberati, Stefania Oliva, Francesca Patriarca, Massimo Offidani, Paola Omedé, Vittorio Montefusco, Maria Teresa Petrucci, Nicola Giuliani, Roberto Passera, Giuseppe Pietrantuono, Mario Boccadoro, Paolo CorradiniAntonio Palumbo

Research output: Contribution to journalArticlepeer-review


A sequential approach including bortezomib induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by lenalidomide consolidation-maintenance, has been evaluated. Efficacy and safety data have been analyzed on intention-to-treat and results updated. Newly diagnosed myeloma patients 65 to 75 years of age (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (100 mg/m2) followed by ASCT (MEL100-ASCT), 4 cycles of lenalidomide-prednisone consolidation (LP), and lenalidomide maintenance (L) until disease progression. The complete response (CR) rate was 33% after MEL100-ASCT, 48% after LP and 53% after L maintenance. After a median follow-up of 66 months, median time-to-progression (TTP) was 55 months and median progression-free survival 48 months. Median overall survival (OS) was not reached, 5-year OS was 63%. In CR patients, median TTP was 70 months and 5-year OS was 83%. Median survival from relapse was 28 months. Death related to adverse events (AEs) occurred in 8/102 patients during induction or transplantation. Rate of death related to AEs was higher in patients ≥70 years compared with younger (5/26 vs 3/76, P = .024). Bortezomib-induction followed by ASCT and lenalidomide consolidation-maintenance is a valuable option for elderly myeloma patients, with the greatest benefit in those younger than 70 years of age.

Original languageEnglish
Pages (from-to)1376-1383
Number of pages8
Issue number8
Publication statusPublished - Aug 22 2013

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Dive into the research topics of 'Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results'. Together they form a unique fingerprint.

Cite this